PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed merger between Pieris Pharmaceuticals, Inc. and Palvella Therapeutics, Inc. Pieris shareholders are expected to own 18% of the combined company.
November 20, 2024 | 10:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pieris Pharmaceuticals is under investigation by Kahn Swick & Foti, LLC regarding its proposed merger with Palvella Therapeutics. Shareholders will own 18% of the new company.
The investigation by a law firm into the merger process could lead to legal challenges or delays, potentially affecting Pieris Pharmaceuticals' stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100